CD34-positive cell ablation

CD34-positive cell ablation has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 11, 2026: “Valve precursor cells promote age-related scarring in mice”.

Exposure

1 paper studies it1 findingUpdated Nov 10, 2026

1 new paper in 30 daysSee all 1 papers on CD34-positive cell ablation

At a glance

The findings reach mice, none yet in people. 1 lab.

1 lab

Animals1

What did studies of CD34-positive cell ablation find?

Studies of CD34-positive cell ablation measured one outcome, aortic valve leaflet thickening.

Aortic valve leaflet thickening

downin mice1

1 study

CD34-positive cell ablation decreases aortic valve leaflet thickening in mice (age-related valve remodeling).
“the systemic or non‐BM‐specific ablation of CD34 + cells or the CD34 + Periostin + transitional subpopulation markedly attenuated age‐related leaflet thickening and fibrotic remodelling.”
Animalsage-related valve remodelingsystemic or non-bone-marrow-specificaortic valve
Valve precursor cells promote age-related scarring in mice
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Nov 10, 2026

Latest

1 paper in 12 months

Advanced ScienceNov 11

Valve precursor cells promote age-related scarring in mice

Removing precursor cells reduced valve thickening and scarring in mice given daily D-galactose injections to model aging for about two months.Removing precursor cells reduced valve thickening and scarring in mice given daily D-galactose injections to model aging for about two months.

Mouse studyMechanisms

Paper